Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Information for Consumers and Patients | Drugs

Information for Consumers and Patients | Drugs

                        Overview of our role regulating and approving drugs | Video series
          Educational Resources | Free Drug-Related Publications


                        Find Information about a Drug
          Buying & Using Medicine Safely
          Encuentre información sobre un medicamento
          Frequently Asked Questions on Popular Topics
          Prescription Drug Advertising
          Tips for Parents
          Tips for Seniors Home
          Drugs
          Resources | Drugs
          Information for Consumers and Patients | Drugs
          MedWatch: Managing Risks at the FDAInformation for Consumers and Patients | Drugs MedWatch: Managing Risks at the FDA
  
  	
    Share
    Post
    Linkedin

    Email
    PrintWhen the Food and Drug Administration approves a medical product, the agency has determined that the benefits of the product outweigh the risks. "But every product the FDA approves carries some risk," says Norman Marks, M.D., director of the FDA's MedWatch program. "And sometimes there are risks that only come to light after a product gets on the market and is used in larger numbers of patients who differ from those studied before approval. They may differ in the complexity of their health problems or other medications that they use, for example."That's where MedWatch comes in.MedWatch, the FDA's safety information and adverse event reporting program, plays a critical role in the agency's postmarketing surveillance--the process of following the safety profile of medical products after they've begun to be used by consumers. Through MedWatch, a voluntary program, health professionals report adverse reactions, product problems, and use errors related to drugs, biologics, medical devices, dietary supplements, cosmetics, and infant formulas."Consumers can also send in reports, but we encourage them to work with a health professional to submit because we'll get a much richer report," Marks says. "Health professionals have clinical information that will help us better evaluate the report."MedWatch especially encourages the reporting of serious adverse reactions. Marks adds, "What we mean by ‘serious' adverse reactions is death and disability, life-threatening problems, hospitalization, congenital anomalies, and other problems that aren't listed on the label as known side effects." MedWatch also accepts reports of product quality problems with drugs or devices, suspected product tampering or counterfeit drugs, medication errors due to packaging problems or name confusion, device use errors, and any other unexpected problems with the product that could pose a safety risk.Once the FDA receives early signals of possible safety issues, the agency can rapidly identify problems and take appropriate actions, including broadcasting new safety information as "MedWatch alerts."Examples of MedWatch alerts for 2003 include:Viga Tablets: The FDA announced a voluntary recall of Viga tablets by Best Life International of Clarkston, Wash. The tablets were sold as a dietary supplement with claims to increase sexual performance. The FDA warned consumers against using the product, which was found to contain the prescription drug sildenafil, even though the ingredient is not listed on the drug's label. Sildenafil is the active ingredient contained in Viagra, a drug available by prescription for treatment of erectile dysfunction. People who are taking nitrates for heart disease should not take sildenafilAn unsuspecting user of Viga tablets could develop life-threatening lowering of blood pressure.Gynecare Intergel Adhesion Prevention Solution: Gynecare Worldwide, a division of Ethicon Inc. of Somerville, N.J., voluntarily withdrew this product and urged customers to immediately stop using the device. The product is intended to be used in gynecological surgery to reduce post-surgical adhesions. There were postmarket reports of several serious problems, including postoperative pain and the need for repeat surgeries.Risperdal (risperidone): Janssen Pharmaceutica Products L.P. of Titusville, N.J., announced important changes to Risperdal, a treatment for schizophrenia. The labeling was updated to include a warning of cerebrovascular problems, including stroke, in elderly people with dementia. The update is based on data from four clinical trials. The company also reminded health professionals that, like other antipsychotic drugs, Risperdal is not indicated to treat dementia."The FDA's MedWatch program has two main goals," Marks says. "We want to facilitate the reporting of problems in to the agency and we want to get safety information out to the public." MedWatch receives about 25,000 voluntary reports each year, which are evaluated along with reports received from manufacturers.The agency has a number of ways to alert the public about important safety information. The MedWatch Web site is an example of one way the agency broadcasts safety information. MedWatch sends e-mail notification of all safety alerts for drugs, biologics, dietary supplements, and devices, as well as monthly safety labeling changes for drugs, to a growing e-mail list of both health care professionals and consumers. By 2004, the number of subscribers to the MedWatch e-mail list jumped to 45,000, from the 5,000 people who signed up in 2000. People on the list receive safety alert summaries by e-mail, with a hyperlink that directs them to more detailed information. It is easy to sign up. Just visit the MedWatch home page at www.fda.gov/medwatch and click on "Join the E-list." Names and e-mail addresses of MedWatch subscribers are not shared with other organizations.MedWatch also works with 170 "MedWatch Partner" organizations to widely disseminate new safety information. For example, the American Pharmacists Association receives e-mail notification of MedWatch safety alerts and includes this information in its own weekly e-mail bulletin, sent to over 64,000 pharmacists nationwide. FDA alerts also appear on a Web site called Pharmacist.com, a joint project of the American Pharmacists Association and the National Association of Boards of Pharmacy.The MedWatch program is also exploring opportunities to work with large health care systems that are already collecting adverse event and medication error reports. "This will facilitate the receipt of these reports by the FDA," Marks says. "We also work with partners like the American Association of Nurse Anesthetists to encourage their members to report to the FDA. It can be hard to get busy health professionals to report, but what we hope is that they see the whole process working--reports coming in from them and the resulting new safety information going back to them in order to make their work easier and their patients safer."After the FDA evaluates reports, the result may be safety alerts, letters to health care professionals, labeling changes, product withdrawals, or further postmarketing research. When the FDA receives a MedWatch report, it is entered into a database that allows a safety evaluator to compare it to similar reports. As few as a handful of reports may trigger a careful investigation by the FDA and a manufacturer."We want the public to know that we depend on their reports," Marks says. "Their reports may prompt timely actions that protect and improve public health."How to Report to MedWatchLog onto the MedWatch site to learn the different ways to submit a report:to report by Internet:www.fda.gov/medwatch/report.htmDownload the reporting form and send to: MedWatch, FDA,5600 Fishers Lane,Rockville, MD 20852-9787 or fax to: (800) FDA-0178 (332-0178)to report by telephone, call (800) FDA-1088 (332-1088)ResourcesForYouProtecting America's Health Through Human Drugs

                                                                                  Content current as of:
      05/04/2016Information for Consumers and Patients | Drugs

          
                        Overview of our role regulating and approving drugs | Video series
          Educational Resources | Free Drug-Related Publications


                        Find Information about a Drug
          Buying & Using Medicine Safely
          Encuentre información sobre un medicamento
          Frequently Asked Questions on Popular Topics
          Prescription Drug Advertising
          Tips for Parents
          Tips for Seniors
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop